Outside from the Ministry of Health.
the Medicines Committee (CIPM) He just celebrated its last meeting, which is the monthly monthly, as the orphan drugs, which were directed to rare diseases, were the main heroes. Specifically, the committee suggested Total or partial financing for five new drugs And four of them agree with OrphansThis is, 80 percent.
Also, at this meeting, it was also agreed to give the green light to Two new indicators on two medications Additional, already approved and previously financed in other indicators. In this way, the balance in these first three months is 13 proposed drugs (9 of them orphans) and 8 new indicators.
This is Five new drugs Who recommended Cipm To finance the national health system (SNS):
• Saadelpar (SEALADELPAR) by Gilead: treatment Primary bile inflammation (CBP) in conjunction with Ursodesoxicolic acid (AUDC) in adults who do not correctly respond to AUDC alone or as a single treatment in patients who do not tolerate AUDC.
• Vanflyta (quizartinib) Dichchi Sancio: Complete therapy with the usual induction chemotherapy with curtains and anthracic Acute healing leukemia (LMA) again the diagnosis that is positive FLT3 IDD.
• Kinpeygo H (Budesonida) De Stada: Treat adults with Globeol immunity kidney devotion (Niga) initial with protein secretion ≥1.0 g/day (or protein/creatinine in urine ≥ 0.8 g/g.
• Servier’s (Ivoyonic) Tibsovo H: Participate with Azassetidine, from adult patients with Acute healing leukemia (LMA) a new diagnosis with a mutation of the Dydrogens -Dydrogens -1 (HDI1) R132, which is not candidate for standard chemotherapy. On the other hand, the treatment in unilateral therapy for adult patients with advanced or metastatic pencil cancer with the IDH1 R132 mutation that has received at least a previous line of physical therapy.
• Alexon Feidia H (Danikoban): Treatment, complement to Ravulizumab or Eculizumab, for adult patients with Night Himoglobin Night (HPN) that have the remaining hemolytic anemia.
Other drug indicators
Two new indicators are added to already funded drugs, including among them Keytruda (Pembrolizumab). In this case, its indication of treatment in mono therapy for adult patients and children from 3 years of age with Classic Hodgkin lymphoma In relapse or thermal, which did not respond to self -implants for blood -constituting fathers or at least two previous treatment when Taph is not a treatment option. Indeed, they also agreed to finance the extension of the IIIA and IIIB stages, and therefore, unable to restrict the approved signal: Keytruda (PMBroolizumab): assistant therapy in adults and adolescents of the age of 12 years with skin cancer in Stadium IIB, IIC or III, and has been subjected to a full appeal.
At the same way, another indicator of Darratumumab has been suggested. This time for compound therapy with cyclophosfamide, Porzomib and Dexamethasone from adult patients with Diagnostic diagnosis of the light chain (AL) again.
Finally, who health They explain that financing The first vital drugs Of the active ingredients omalizumab and AFLIBERPTT. On the one hand, omlyclo (omalizumab) Allergy asthma, Chronic ginosinitis with chronic automatic nose and etc. On the other hand, AFQLIR (AFLIBERPT) of macular degeneration associated with vascular ages (Nabar); Visual change Because of the secondary magy to block the network vein or the central vein of the retina; Visual change due to diabetic macular edema (EMD); And visual change.
The information published in the medical writing contains data, data and data from official institutions and health professionals. However, given any questions related to your health, consult the opposite health specialist.
